Castle Biosciences, Inc. (CSTL) Profit Margins
Over the twelve months to 2026-06-30, Castle Biosciences, Inc. (CSTL) had gross margin 77.3%, operating margin -9.0%, net margin -5.4%, free cash flow margin -0.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CSTLCastle Biosciences, Inc.Follow CSTL — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 85.9% | 84.5% | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% | 77.3% | |
| Operating margin | 14.1% | -10.4% | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% | -9.0% | |
| Net margin | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% | -5.4% | |
| FCF margin | 11.7% | 8.2% | -23.9% | -34.5% | -8.8% | 11.0% | 8.2% | -0.1% |
USD millions · SEC XBRL
Castle Biosciences, Inc. — questions
- What is Castle Biosciences, Inc.'s gross margin?
- 77.3% over the twelve months to 2026-06-30.
- What is Castle Biosciences, Inc.'s operating margin?
- -9.0% over the twelve months to 2026-06-30.
- What is Castle Biosciences, Inc.'s net profit margin?
- -5.4% over the twelve months to 2026-06-30.
Every figure on this page comes from Castle Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.